Physician

Babak Rajabi, MD

According to 2025 Medicare claims, Babak Rajabi, MD (NPI: 1194986794) practices medical oncology in the Sacramento-Roseville-Folsom, CA market, with the plurality of this provider's patient population coming from Sacramento, CA. This provider's primary affiliated billing organization is SIERRA HEMATOLOGY AND ONCOLOGY MEDICAL CENTERS (NPI: 1992796759; TIN: 680305843) and primary practice location at 95630-3888. Rajabi is affiliated with the Vivant Health ACO (ACO ID: A5068), participating under the MSSP model.

Rajabi's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 341 traditional Medicare patients, billed 155,403 HCPCS/CPT codes, and received $2,267,922 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,218 prescription claims across 157 beneficiaries totaling $3,420,316 in drug costs, led by Jakafi (Ruxolitinib Phosphate). DME data shows 41 claims. Open Payments data shows 55 records totaling $2,854. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $126,071 to $2,267,922. Similarly, Part D prescription costs have risen steadily, from $949,211 to $3,420,316. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	700	1,762	$126,071
2016	427	22,793	$201,062
2017	344	58,003	$810,004
2018	299	87,851	$973,372
2019	286	131,610	$1,198,538
2020	243	89,630	$1,151,136
2021	271	77,529	$984,817
2022	340	186,498	$1,452,796
2023	333	223,140	$2,062,198
2024	341	155,403	$2,267,922

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	227	1,158	$949,211
2016	158	520	$290,397
2017	105	466	$422,947
2018	112	646	$1,130,472
2019	95	623	$1,320,403
2020	96	698	$2,030,913
2021	99	667	$1,987,404
2022	161	921	$2,490,083
2023	171	1,059	$2,790,613
2024	157	1,218	$3,420,316

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	52	280	$80,140
2016	N/R	69	$16,079
2017	N/R	N/R	N/R
2018	N/R	15	$4,962
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	41	$1,543
2023	N/R	40	$4,476
2024	N/R	41	$1,577

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	178	698	$104
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	111	219	$71
80053	Blood test, comprehensive group of blood chemicals	78	312	$10
36415	Insertion of needle into vein for collection of blood sample	140	555	$8
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	142	800	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Jakafi	Ruxolitinib Phosphate	26	780	$491,491
Revlimid	Lenalidomide	24	630	$389,118
Brukinsa	Zanubrutinib	27	810	$369,440
Pomalyst	Pomalidomide	13	364	$298,334
Venclexta	Venetoclax	22	646	$275,340

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
E1390	Oxygen concentrator, single delivery port, capable of delivering 85 percent or greater oxygen concentration at the prescribed flow rate	Y	N/R	13	$898
J8521	Capecitabine, oral, 500 mg	N	N/R	15	$434
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	13	$245

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	55	$2,854	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Babak Rajabi, MD?

Tedicare shows public-source Medicare data for Babak Rajabi, MD (NPI 1194986794), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Babak Rajabi, MD have ACO affiliation data?

Babak Rajabi, MD is shown with ACO affiliation data for Vivant Health ACO (MSSP, ACO ID A5068).

What billing organization is linked to Babak Rajabi, MD?

Babak Rajabi, MD is linked to SIERRA HEMATOLOGY AND ONCOLOGY MEDICAL CENTERS (billing NPI 1992796759) in the available physician profile data.

Does Babak Rajabi, MD have Open Payments data?

Babak Rajabi, MD has 55 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.